Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits
- 7 March 2025
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (4) , 647-656
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United StatesThe American Journal of Cardiology, 2023
- Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community PracticeJAMA Cardiology, 2023
- Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration SystemJAMA, 2022
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the USJAMA Network Open, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Therapeutic Inertia in Cardiovascular Disease PreventionJACC, 2019
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by CardiologistsJACC, 2019
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration LabelingJACC, 2018
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007